# NCT03677141 (NCT03677141)

> A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03677141
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: B-cell Non-Hodgkin Lymphoma
- Interventions: Mosunetuzumab; Polatuzumab Vedotin; Rituxumab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone; Tocilizumab
- Enrollment: 117
- Primary outcome: Complete Response (CR) Rate at the Time of Primary Response Assessment (PRA) Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Determined by Independent Review Committee (IRC)

## Indexed commentary on NCT03677141 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03677141